Literature DB >> 34002890

RT-QuIC Detection of Pathological α-Synuclein in Skin Punches of Patients with Lewy Body Disease.

Angela Mammana1, Simone Baiardi1,2, Corinne Quadalti1, Marcello Rossi1, Vincenzo Donadio1, Sabina Capellari1,3, Rocco Liguori1,3, Piero Parchi1,2.   

Abstract

BACKGROUND: Evidence suggests that skin represents a suitable matrix for demonstrating α-synuclein oligomers as a diagnostic biomarker for Lewy body disease.
OBJECTIVE: The objective of this study was to evaluate the diagnostic performance of skin α-syn real-time quaking-induced conversion assay in patients with Lewy body disease.
METHODS: We analyzed skin punches taken in vitam (n = 69) or postmortem (n = 49) from patients with PD, dementia with Lew bodies (DLB), incidental Lewy body pathology, and neurological controls. Seventy-nine patients underwent both CSF and skin α-synuclein real-time quaking-induced conversion assay.
RESULTS: Overall, the skin α-synuclein real-time quaking-induced conversion assay distinguished Lewy body disease patients with 94.1% accuracy (sensitivity, 89.2%; specificity, 96.3%). Assay sensitivity reached 94.1% in the 17 Lewy body disease patients analyzed in the cervical region. In patients with both CSF and skin samples, the 2 real-time quaking-induced conversion assay protocols yielded similar diagnostic accuracy (skin, 97.5%; CSF, 98.7%).
CONCLUSION: Skin punch biopsies might represent a valid and convenient alternative to CSF analysis to demonstrate Lew body-related α-synuclein deposition in patients with Lewy body disease.
© 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  CSF; biomarker; prions; real-time quaking-induced conversion; synucleinopathies

Year:  2021        PMID: 34002890     DOI: 10.1002/mds.28651

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  8 in total

1.  Application of α-Syn Real-Time Quaking-Induced Conversion for Brain and Skin Specimens of the Chinese Patients With Parkinson's Disease.

Authors:  Dong-Dong Chen; Ling Jiao; Yue Huang; Kang Xiao; Li-Ping Gao; Cao Chen; Qi Shi; Xiao-Ping Dong
Journal:  Front Aging Neurosci       Date:  2022-07-01       Impact factor: 5.702

2.  The Alpha-Synuclein RT-QuIC Products Generated by the Olfactory Mucosa of Patients with Parkinson's Disease and Multiple System Atrophy Induce Inflammatory Responses in SH-SY5Y Cells.

Authors:  Chiara Maria Giulia De Luca; Alessandra Consonni; Federico Angelo Cazzaniga; Edoardo Bistaffa; Giuseppe Bufano; Giorgia Quitarrini; Luigi Celauro; Giuseppe Legname; Roberto Eleopra; Fulvio Baggi; Giorgio Giaccone; Fabio Moda
Journal:  Cells       Date:  2021-12-28       Impact factor: 6.600

Review 3.  Neuropathology and molecular diagnosis of Synucleinopathies.

Authors:  Shunsuke Koga; Hiroaki Sekiya; Naveen Kondru; Owen A Ross; Dennis W Dickson
Journal:  Mol Neurodegener       Date:  2021-12-18       Impact factor: 14.195

4.  High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease.

Authors:  Marco J Russo; Christina D Orru; Luis Concha-Marambio; Simone Giaisi; Bradley R Groveman; Carly M Farris; Bret Holguin; Andrew G Hughson; David-Erick LaFontant; Chelsea Caspell-Garcia; Christopher S Coffey; Jennifer Mollon; Samantha J Hutten; Kalpana Merchant; Roland G Heym; Claudio Soto; Byron Caughey; Un Jung Kang
Journal:  Acta Neuropathol Commun       Date:  2021-11-06       Impact factor: 7.801

5.  Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change.

Authors:  Denis S Smirnov; Nicholas J Ashton; Kaj Blennow; Henrik Zetterberg; Joel Simrén; Juan Lantero-Rodriguez; Thomas K Karikari; Annie Hiniker; Robert A Rissman; David P Salmon; Douglas Galasko
Journal:  Acta Neuropathol       Date:  2022-02-23       Impact factor: 15.887

Review 6.  RT-QuIC and Related Assays for Detecting and Quantifying Prion-like Pathological Seeds of α-Synuclein.

Authors:  Ankit Srivastava; Parvez Alam; Byron Caughey
Journal:  Biomolecules       Date:  2022-04-14

Review 7.  The Future of Seed Amplification Assays and Clinical Trials.

Authors:  Thomas Coysh; Simon Mead
Journal:  Front Aging Neurosci       Date:  2022-06-22       Impact factor: 5.702

8.  Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson's disease.

Authors:  Matilde Bongianni; Mauro Catalan; Daniela Perra; Elena Fontana; Francesco Janes; Claudio Bertolotti; Luca Sacchetto; Stefano Capaldi; Matteo Tagliapietra; Paola Polverino; Valentina Tommasini; Giulia Bellavita; Elham Ataie Kachoie; Roberto Baruca; Andrea Bernardini; Mariarosaria Valente; Michele Fiorini; Erika Bronzato; Stefano Tamburin; Laura Bertolasi; Lorenzo Brozzetti; Maria Paola Cecchini; Gianluigi Gigli; Salvatore Monaco; Paolo Manganotti; Gianluigi Zanusso
Journal:  Transl Neurodegener       Date:  2022-07-28       Impact factor: 9.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.